Key Considerations When Selecting EGFR Inhibitor Treatments in NSCLC - Episode 2
Presenting the Treatment Options in EGFR-Mutant NSCLC: Weighing the Data and Incorporating the Patient Perspective
Panelists discuss how conversations with patients about treatment options have become more complex and nuanced, requiring thorough explanation of efficacy data and adverse effects while adapting to each patient’s level of understanding and involvement.
Video Player is loading.
Video content above is prompted by the following:
Communication Strategies for Treatment Decision-Making
Key Themes:
- Shared Decision-Making: Challenges in presenting complex clinical trial data to patients in time-constrained clinical settings
- Patient Education: Balancing efficacy outcomes with toxicity profiles when discussing treatment options
- Individualized Approach: Recognizing that patient preferences and knowledge vary significantly
Notable Insights:
- Dr Piotrowska: “I think the best way to do this is to try to talk about it and then give patients a little bit of time to digest and think through these options, and maybe not make a final decision in that initial visit.” She also acknowledges that clinicians bring their own biases to these conversations.
- Dr Dietrich: Notes the importance of recognizing different patient information needs, stating “Some patients are very informed...and some others are deferring more to me.” He emphasized that these discussions have become “significantly harder, both on the discussion about efficacy and the nuances of [adverse] effects.”
Related Content:
